Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis.

Haohua LU; Yu Shi; Kelie Chen; Zhi Chen; Haihong Zhu; Yuequn Niu; Dajing Xia; Yihua WU

Return

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis.

Author: Haohua LU ¹ ; Yu SHI ² ; Kelie CHEN ¹ ; Zhi CHEN ³ ; Haihong ZHU ⁴ ; Yuequn NIU ¹ ; Dajing XIA ⁵ ; Yihua WU ⁶
Author Information

1. Department of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
2. The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
3. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China.
4. National Clinical Research Center for Infectious Diseases, Hangzhou 310003, China.
5. Department of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. dxia@zju.edu.cn.
6. Department of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. georgewu@zju.edu.cn.
Publication Type:Journal Article
Keywords: Anti-tumor regimens; COVID-19; Cancer; Pooled analysis
MeSH: Adult; Aged; Aged, 80 and over; COVID-19/complications*; Female; Humans; Male; Middle Aged; Neoplasms/therapy*; SARS-CoV-2
From: Journal of Zhejiang University. Science. B 2021;22(10):876-884
CountryChina
Language:English
Abstract: Since the outbreak of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discovered in December 2019, the disease has emerged as a global pandemic (Shi et al., 2020; World Health Organization, 2020). Several studies have shown a higher incidence of COVID-19, as well as related poor outcomes in patients with malignancies as compared with those without them (Liang et al., 2020; Tian et al., 2020). The impact of cancer on COVID-19 may be attri‑buted to the use of antitumor treatments that may disturb the host response to SARS-CoV-2 infection (Wang et al., 2020), while the current studies on this topic have drawn controversial conclusions. Some implied that anticancer treatments might elevate the risk of death (García-Suárez et al., 2020; Liu et al., 2020). On the contrary, others pointed out that this association is not significant (Brar et al., 2020; Lee et al., 2020a). Although previous systematic reviews have investigated this important issue (Wang and Huang, 2020), the heterogeneity of findings is obvious and the general conclusion has remained unclear. Considering this ambiguity, it is difficult for clinicians to make therapeutic decisions when facing patients with both cancer and COVID-19; therefore, a high-quality and accurate evaluation of the impact of anticancer treatments on COVID-19 patients is necessary. Accordingly, we conducted a pooled analysis with the original data of each patient for the first time to provide a comprehensive perspective into the association between anticancer regimens and the outcomes of cancer patients with COVID-19.